Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

NCT05706779 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
BRAF V600E Mutation Positive

Interventions

DRUG: Encorafenib Oral Capsule + Cetuximab

Sponsor

Federation Francophone de Cancerologie Digestive

Collaborators

[object Object]
[object Object]